GEP-NETs & LUTATHERA® (lutetium Lu 177 dotatate)

Don’t wait: Patients with progressing GEP-NETs deserve targeted treatment now^1-4

Constant Risk of Progression. 3 out of 4 PATIENTS saw their tumor become more aggressive with time. Poor Outcomes 1 out of 2 PATIENTS with grade 2 GEP-NETs die within 5 years (Ki-67 index > 10%). Not actual patients.

How can you help your patient stay ahead of GEP-NET progression?

*Data from a study of 43 patients with well-differentiated NETs of different primary sites (including lung) over time. Sixteen patients (37%) were identified with grade changes (time interval of 4-81 months).²
^†In a study of patients with grade 3 GEP-NETs (N=26), mOS was 19 months without treatment.⁶

When treating GEP-NETs, start with LUTATHERA ASAP

Aggressive start or after progression (ASAP). Treat 1L patients with LUTATHERA with aggressive disease (Grade 2/3 (Ki-67 ≥ 10%). Or, treat 2L patients with LUTATHERA after progression on SSA monotherapy regardless of grade

Which of your patients is ready to START LUTATHERA ASAP?

See hypothetical patients

1L, first line; 2L, second line; GEP-NETs, gastroenteropancreatic neuroendocrine tumors; mOS, median overall survival; NETs, neuroendocrine tumors; SSA, somatostatin analogue.

<Previous: Home

Next: Patient Identification>

References: 1. Panzuto F, Cicchese N, Partelli S, et al. Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms. PLoS ONE. 2017;12(6):e0179445. 2. Singh S, Hallet J, Rowsell C, Law CH. Variability of Ki67 labeling index in multiple neuroendocrine tumors specimens over the course of the disease. Eur J Surg Oncol. 2014;40(11):1517-1522. 3. Botling J, Lamarca A, Bajic D, et al. High-grade progression confers poor survival in pancreatic neuroendocrine tumors. Neuroendocrinology. 2020;110(11-12):891-898. 4. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol. 2010;21(9):1794-1803. 5. Varghese DG, Del Rivero J, Bergsland E. Grade progression and intrapatient tumor heterogeneity as potential contributors to resistance in gastroenteropancreatic neuroendocrine tumors. Cancers (Basel). 2023;15(14):3712. 6. Lithgow K, Venkataraman H, Hughes S, et al. Well-differentiated gastroenteropancreatic G3 NET: findings from a large single centre cohort. Sci Rep. 2021;11(1):17947. 7. Data on file. Novartis Pharmaceuticals Corp; 2021. 8. Lutathera. Prescribing information. Novartis Pharmaceuticals Corp.

Don’t wait: Patients with progressing GEP-NETs deserve targeted treatment now^1-4

When treating GEP-NETs, start with LUTATHERA ASAP

Important Safety Information

Indication

Don’t wait: Patients with progressing GEP-NETs deserve targeted treatment now1-4

When treating GEP-NETs, start with LUTATHERA ASAP

Don’t wait: Patients with progressing GEP-NETs deserve targeted treatment now^1-4